此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Ultrasound-Guided Thoracolumbar Fascia Injection for Chronic Low Back Pain in Patients With Type 2 Diabetes

2026年11月4日 更新者:Hatice Zehra FERHATLAR

Efficacy of Ultrasound-Guided Thoracolumbar Fascia Injection in the Treatment of Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial

This prospective, randomized, controlled clinical trial aims to evaluate the efficacy of ultrasound-guided thoracolumbar fascia (TLF) injection as an adjunct to standard conservative treatment in patients with type 2 diabetes mellitus and chronic nonspecific low back pain.

A total of 60 patients aged 18-65 years, diagnosed with type 2 diabetes mellitus for at least one year and experiencing chronic nonspecific low back pain for at least three months, will be enrolled. Eligible participants will be randomly assigned to two groups. The intervention group will receive ultrasound-guided thoracolumbar fascia injection in addition to standard conservative treatment, while the control group will receive standard conservative treatment alone, consisting of patient education and a structured exercise program.

Clinical assessments will be performed at baseline and at 1 and 3 months after treatment. Treatment outcomes will include pain intensity measured using the Numeric Rating Scale (NRS), functional disability assessed using the Oswestry Disability Index (ODI), pressure pain threshold (PPT) measured by algometry, and analgesic consumption.

Thoracolumbar fascia thickness will be measured using ultrasonography at baseline to investigate its potential association with treatment response. Diabetes-related characteristics, including HbA1c levels, diabetes duration, and peripheral neuropathy status, will also be recorded.

The primary objective is to determine whether adding ultrasound-guided thoracolumbar fascia injection to standard conservative treatment provides greater improvement in pain intensity and functional disability compared with standard conservative treatment alone. The study will also explore whether baseline thoracolumbar fascia thickness and diabetes-related characteristics are associated with clinical outcomes.

研究概览

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

**Inclusion Criteria:**

  • Age between 18 and 65 years.
  • Diagnosis of type 2 diabetes mellitus for at least 1 year.
  • Chronic low back pain lasting at least 3 months.
  • Nonspecific or mechanical low back pain.
  • Baseline pain intensity of ≥4 on the Numeric Rating Scale (NRS).
  • Pain or tenderness on palpation over the thoracolumbar fascia region.
  • Willingness to participate in the study.
  • Provision of written informed consent.

**Exclusion Criteria:**

  • Radiculopathy or significant neurological deficits.
  • Neurogenic claudication due to spinal stenosis.
  • Spinal tumor or infection.
  • History or presence of vertebral fracture.
  • Inflammatory rheumatic disease.
  • Spinal surgery within the previous 6 months.
  • Injection in the lumbar region within the previous 3 months.
  • Anticoagulant therapy or conditions contraindicating injection.
  • Active infection at the injection site.
  • Severe systemic disease, including advanced renal failure.
  • Uncontrolled diabetic metabolic condition.
  • Pregnancy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Thoracolumbar Fascia Injection Group

A single ultrasound-guided thoracolumbar fascia injection will be performed with the patient in the prone position under aseptic conditions. Using an in-plane technique, a 22-gauge needle will be advanced into the middle layer of the thoracolumbar fascia between the quadratus lumborum and erector spinae muscles at the L4 level. Correct needle placement will be confirmed by hydrodissection using approximately 2 mL of local anesthetic. Subsequently, 10 mL of 0.25% bupivacaine and 40 mg of methylprednisolone acetate will be administered into the interfascial plane.

Standard conservative treatment will consist of structured patient education and a home-based exercise program. The exercise program will include lumbopelvic and core stabilization exercises, abdominal and paraspinal muscle strengthening, hip muscle strengthening, lower extremity stretching, and aerobic activity as tolerated. Participants will receive instructions on correct exercise techniques, maintaining daily activities, and avoiding prolonged bed rest. The program will be recommended for regular home practice throughout the study period.

有源比较器:Standard Conservative Treatment Group

Standard conservative treatment will consist of structured patient education and a home-based exercise program. The exercise program will include lumbopelvic and core stabilization exercises, abdominal and paraspinal muscle strengthening, hip muscle strengthening, lower extremity stretching, and aerobic activity as tolerated. Participants will receive instructions on correct exercise techniques, maintaining daily activities, and avoiding prolonged bed rest. The program will be recommended for regular home practice throughout the study period.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Change in Low Back Pain Intensity Measured by the Numeric Rating Scale (NRS)
大体时间:Baseline, Month 1, and Month 3
Baseline, Month 1, and Month 3

次要结果测量

结果测量
大体时间
Change in Functional Disability Measured by the Oswestry Disability Index (ODI)
大体时间:Baseline, Month 1, and Month 3
Baseline, Month 1, and Month 3
Change in Pressure Pain Threshold (PPT) Measured by Algometry
大体时间:Baseline, Month 1, and Month 3
Baseline, Month 1, and Month 3
Change in Analgesic Consumption During Follow-up
大体时间:Baseline to Month 3
Baseline to Month 3

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月23日

初级完成 (估计的)

2027年4月30日

研究完成 (估计的)

2027年4月30日

研究注册日期

首次提交

2026年11月4日

首先提交符合 QC 标准的

2026年11月4日

首次发布 (实际的)

2026年11月10日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅